Russian Journal of Child NeurologyRussian Journal of Child NeurologyРусский журнал детской неврологии2073-88032412-9178Publishing House ABV Press45810.17650/2073-8803-2024-19-1-25-40REVIEWS AND LECTURESОБЗОРЫ И ЛЕКЦИИEfficacy and tolerability of sulthiame in the treatment of epilepsy: a literature reviewЭффективность и переносимость сультиама в лечении эпилепсии: обзор литературыhttps://orcid.org/0000-0001-8855-7740MukhinK. Yu.МухинК. Ю.
Russian Federation

Konstantin Yuryevich Mukhin

5, 8 Nagornaya St., Troitsk, Moscow 108842

9 Akademika Anokhina St., Moscow 119579

Константин Юрьевич Мухин

108842 Москва, Троицк, ул. Нагорная, 5, 8

119579 Москва, ул. Академика Анохина, 9

center@epileptologist.ruhttps://orcid.org/0000-0001-9050-2036PylaevaO. A.ПылаеваО. А.
Russian Federation

5, 8 Nagornaya St., Troitsk, Moscow 108842

9 Akademika Anokhina St., Moscow 119579

108842 Москва, Троицк, ул. Нагорная, 5, 8

119579 Москва, ул. Академика Анохина, 9

https://orcid.org/0000-0001-9510-4918МarkinА. V.МаркинА. В.
Russian Federation

5, 8 Nagornaya St., Troitsk, Moscow 108842

9 Akademika Anokhina St., Moscow 119579

108842 Москва, Троицк, ул. Нагорная, 5, 8

119579 Москва, ул. Академика Анохина, 9

Svt. Luka’s Institute of Child Neurology and EpilepsyООО «Институт детской неврологии и эпилепсии им. Святителя Луки»Svt. Luka’s Institute of Child and Adult Neurology and EpilepsyООО «Институт детской и взрослой неврологии и эпилепсии им. Святителя Луки150120241910704202407042024Copyright ©; 2024, ABV-PressCopyright ©; 2024, АБВ-пресс2024ABV-PressАБВ-прессhttps://rjdn.abvpress.ru/jour/about/editorialPolicieshttps://rjdn.abvpress.ru/jour/article/view/458

This review aims to summarize the available evidence on the efficacy and tolerability of sulthiame for different forms of epilepsy. The analysis of international publications suggests that sulthiame is considered as a first-line drug for the treatment of age-dependent epilepsy with central temporal spikes (rolandic epilepsy). Sulthiame is highly effective in children with epileptic encephalopathies manifesting with spike-and-wave activity during sleep, including Landau-Kleffner syndrome, as well as in patients with myoclonic seizures. The drug might be also effective in patients with other forms of focal epilepsy, including those resistant to therapy. The tolerability of sulthiame is higher that that of old antiepileptic drugs and even levetiracetam; thus, it is associated with a lower risk of treatment interruptions due to adverse events. Moreover, sulthiame can be used for behavioral disorders (such as hyperkinetic behavior, aggressiveness) and cognitive impairments. Sulthiame can be effective in patients with epilepsy and sleep apnea.

Авторы представляют обзор литературы, посвященной эффективности и переносимости сультиама в лечении различных форм эпилепсии. Обзор международных публикаций показал, что в мире сультиам рассматривается как препарат первого выбора для лечения возрастзависимой эпилепсии с центрально-темпоральными спайками (роландической эпилепсии). Сультиам высокоэффективен у пациентов детского возраста с эпилептическими энцефалопатиями, проявляющимися феноменом спайк-волновой активации во сне, включая синдром Ландау–Клеффнера, а также при миоклонических приступах, и может быть эффективен у пациентов с другими формами фокальной эпилепсии, в том числе резистентными к терапии. Лечение сультиамом сопряжено с низким риском отмены из-за плохой переносимости, и сультиам превосходит по этому показателю не только старые антиэпилептические препараты, но и такие новые препараты, как леветирацетам. Отдельной сферой терапевтического применения сультиама служат поведенческие (гиперкинетическое поведение, агрессивность) и когнитивные нарушения у пациентов с эпилепсией. Сультиам также может быть эффективен у пациентов с эпилепсией и ночным апноэ.

sulthiameage-dependent epilepsy with central temporal spikes (rolandic epilepsy)epileptic encephalopathyspike-and-wave activity during sleepfocal epilepsyefficacytolerabilityсультиамвозрастзависимая эпилепсия с центрально-темпоральными спайками (роландическая эпилепсия)эпилептическая энцефалопатияфеномен спайк-волновой активации во снефокальные эпилепсииэффективностьпереносимостьMukhin K.Yu., Petrukhin A.S. Epileptic syndromes. Clinical and electroencephalographic diagnostics and therapy. In: Epileptic syndromes. Diagnosis and therapy (a guideline for doctors). Moscow: Russkiy pechatnyy dvor, 2023. Pp. 146–323. (In Russ.)Мухин К.Ю., Петрухин А.С. Эпилептические синдромы. Клинико-электроэнцефалографическая диагностика и терапия. В кн.: Эпилептические синдромы. Диагностика и терапия (руководство для врачей). М.: Русский печатный двор, 2023. С. 146–323.Mukhin K.Yu., Pylaeva O.A. New classification of epileptic syndromes of the International League Against Epilepsy (2022): Basic definitions and principles; differences from the draft classification; comments and discussion. Vestnik epileptologii = Bulletin of Epileptology 2022:4–14. (In Russ.)Мухин К.Ю., Пылаева О.А. Новая классификация эпилептических синдромов Международной противоэпилептической лиги (2022 г.): основные дефиниции и принципы; отличия от проекта классификации; комментарии и обсуждение. Вестник эпилептологии 2022:4–14.Mukhin K.Yu., Petrukhin A.S., Mironov M.B. et al. Epilepsy with electrical status epilepticus during slow-wave sleep: Diagnostic criteria, differential diagnosis and approaches to therapy. Moscow, 2005. 32 p. (In Russ.)]Мухин К.Ю., Петрухин А.С., Миронов М.Б. и др. Эпилепсия с электрическим эпилептическим статусом медленного сна: диагностические критерии, дифференциальный диагноз и подходы к терапии. М., 2005. 32 с.Mukhin K.Yu. Idiopathic focal epilepsy with pseudogeneralized seizures: A special form of epilepsy in children. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2009;4(2):3–19. (In Russ.)Мухин К.Ю. Идиопатическая фокальная эпилепсия с псевдогенерализованными приступами – особая форма эпилепсии в детском возрасте. Русский журнал детской неврологии 2009;4(2):3–19.Muhin K.Yu., Pylaeva O.A., Kakaulina V.S., Bobylova M.Yu. International classification of epileptic syndromes 2021 and its discussion. Moscow: Russkiy pechatnyy dvor, 2022. 160 p. (In Russ.)Мухин К.Ю., Пылаева О.А., Какаулина В.С., Бобылова М.Ю. Проект международной классификации эпилептических синдромов 2021 г. с обсуждением. М.: Русский печатный двор, 2022. 160 с.Pylaeva O.A., Mukhin K.Yu. Side effects of antiepileptic therapy: General principles and prevention algorithms. In: Epileptic syndromes. Diagnosis and therapy. Guideline for doctors. 5th edn. Moscow: Russkiy pechatnyy dvor, 2023. Pp. 540–596. (In Russ.)Пылаева О.А., Мухин К.Ю. Побочные эффекты антиэпилептической терапии: общие закономерности развития и принципы профилактики. В кн.: Эпилептические синдромы. Диагностика и терапия. Руководство для врачей. 5-е изд-е. М.: Русский печатный двор, 2023. С. 540–596.Pylaeva O.A., Mukhin K.Yu., Petrukhin A.S. Side effects of antiepileptic medication. Moscow: Granat, 2016. 232 p. (In Russ.)Пылаева О.А., Мухин К.Ю., Петрухин А.С. Побочные эффекты антиэпилептической терапии. М.: Гранат, 2016. 232 c.Epilepsy. Atlas of electroclinical diagnostics and therapy. Vol. 1. Moscow: Russkiy pechatnyy dvor, 2023. 912 p. (In Russ.)Эпилепсия. Атлас электроклинической диагностики и терапии. Tом 1. М.: Русский печатный двор, 2023. 912 с.Al Kaisi A.H., McGuire R.J. The effect of sulthiame on disturbed behaviour in mentally subnormal patients. Brit J Psychiatry 1974;124:45–9. DOI: 10.1192/bjp.124.1.45Bast T., Völp A., Wolf C. et al. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia 2003;44:215–20.Ben-Zeev B., Watemberg N., Lerman P. et al. Sulthiame in childhood epilepsy. Pediatr Int 2004;46(5):521–4.Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia 2002;43:469–74.Borusiak P., Langer Th., Heruth M. et al. Antiepileptic drugs and bone metabolism in children: Data from 128 patients. J Child Neurol 2013;28(2):176–83.Congress 2022: Highlights from the Sleep Disordered Breathing Assembly. ERJ Open Res 2023;9(2):00582–2022. DOI: 10.1183/23120541.00582-2022Bradicich M., Siciliano M., Schiavi E. et al. ERS InternationalCampos M.S., Ayres L.R., Morelo M.R. et al. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: Systematic review and network meta-analyses. Pharmacotherapy 2016;36(12):1255–71. DOI: 10.1002/phar.1855Caraballo R., Reyes G., Semprino M. et al. Use of sulthiame as add-on therapy in children with non-self-limited focal epilepsies of childhood. Epilepsy Behav 2023;143:109220. DOI: 10.1016/j.yebeh.2023.109220Caraballo R.H., Flesler S., Reyes Valenzuela G. et al. Sulthiame add-on therapy in children with Lennox–Gastaut syndrome: A study of 44 patients. Seizure 2018;62:55–8. DOI: 10.1016/j.seizure.2018.09.019Caraballo R.H., Reyes Valenzuela G., Fortini S. et al. Use of sulthiame as add-on therapy in children with myoclonic atonic epilepsy: A study of 35 patients. Epilepsy Behav 2022;131(Pt A): 108702. DOI: 10.1016/j.yebeh.2022.108702Cheng W., Yang Y., Chen Y. et al. Anti-seizure medication treatment of benign childhood epilepsy with centrotemporal spikes: A systematic review and meta-analysis. Front Pharmacol 2022;13:821639. DOI: 10.3389/fphar.2022.821639Dao K., Thoueille P., Decosterd L.A. et al. Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. Pharmacol Res Perspect 2020;8(1):e00558. DOI: 10.1002/prp2.558Davico C., Canavese C., Vittorini R. et al. Anticonvulsants for psychiatric disorders in children and adolescents: A systematic review of their efficacy. Front Psychiatry 2018;9:270.Doose H., Baier W.K., Ernst J.-P. et al. Benign partial epilepsy – treatment with sulthiame. Develop Med Child Neurol 1988;30:683, 684. DOI: 10.1111/j.1469-8749.1988.tb04809.xFejerman N., Caraballo R. Benign focal epilepsies in infancy, childhood and adolescence. UK: JL Eurotext, 2007. 266 p.Fong Сh.Y., Hashim N., Gan Ch.S. et al. Sulthiame-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Eur J Paediatr Neurol 2016;20(6):957–61.Gerstl L., Willimsky E., Remi C. et al. A systematic review of seizure-freedom rates in patients with benign epilepsy of childhood with centrotemporal spikes receiving antiepileptic drugs. Clin Neuropharmacol 2021;44(2):39–46. DOI: 10.1097/WNF.0000000000000435Gobbi G., Grosso S. Atypical benign partial epilepsy of childhood. In: Atlas of Epilepsies. London: Springer, 2010. Pp. 923–930.Gorman K.M., Shahwan A. Sultiame revisited: Treatment of refractory absence seizures. Epileptic Disord 2016;18(3):329–33. DOI: 10.1684/epd.2016.0850Guerrini R., Marini C. Epileptic encephalopathies. In: Epilepsy and Epileptic Seizures. Oxford: Oxford University Press, 2013. Pp. 177–185.Guerrini R., Mari F., Auvin S., Dravet Ch. Myoclonic epilepsies in infancy and early childhood. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th edn. Paris: John Libbey Eurotext Ltd., 2019. Pp. 173–188.Hadi D.A., Mohamed A.R., Rethanavelu K., Khoo T.B. Clonic seizures, continuous spikes-and-waves during slow sleep, choreoathetosis and response to sulthiame in a child with FRRS1L encephalopathy. Brain Dev 2022;44(1):44–9. DOI: 10.1016/j.braindev.2021.08.006Hedner J., Stenlof K., Zou D. et al. A randomized controlled clinical trial exploring safety and tolerability of sulthiame in sleep apnea. Am J Respir Crit Care Med 2022;205(12):1461–9. DOI: 10.1164/rccm.202109-2043OCHeger K., Skipsfjord J., Kiselev Y. et al. Changes in the use of antiseizure medications in children and adolescents in Norway, 2009–2018. Epilepsy Res 2022;181:106872. DOI: 10.1016/j.eplepsyres.2022.106872Hoff E., Strassberger C., Zou D. et al. Modification of endotypic traits in OSA by the carbonic anhydrase inhibitor sulthiame. Chest 2023:S0012-3692(23)05544-7.Josephson C.B., Gonzalez-Izquierdo A., Denaxas S. et al. Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing antiseizure medications with the development of osteoporosis. JAMA Neurol 2023;80(8):843–50. DOI: 10.1001/jamaneurol.2023.1580Kanmaz S., Simsek E., Serin H.M. et al. Sulthiame add-on treatment in children with epileptic encephalopathy with status epilepticus: an efficacy analysis in etiologic subgroups. Neurol Sci 2021;42(1):183–91. DOI: 10.1007/s10072-020-04526-yKramer U., Sagi L., Goldberg-Stern H. et al. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). Epilepsia 2009;50(6):1517–24.Leniger T., Wiemann M., Bingmann D. et al. Comorbidity between epilepsy and sleep disorders. Epilepsy Res 2020;90(3):171–7.Milburn-McNulty P., Panebianco M., Marson A.G. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev 2021;9(9): CD010062. DOI: 10.1002/14651858.CD010062.pub3Miranda M.J., Ahmad B.B. Treatment of rolandic epilepsy. Ugeskr Laeger 2017;179(48):V06170482.Moffatt W.R., Siddiqui A.R., MacKay D.N. The use of sulthiame with disturbed mentally subnormal patients. Brit J Psychiatry 1970;117(541):673–8. DOI: 10.1192/bjp.117.541.673Nobili L., de Weerd A., Rubboli G. et al. Standard procedures for the diagnostic pathway of sleep-related epilepsies and comorbid sleep disorders: An EAN, ESRS and ILAE-Europe consensus review. Eur J Neurol 2021;28(1):15–32. DOI: 10.1111/ene.14468Oguni H., Tanaka T., Hayashi K. et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002;33:122–32.Oguni H., Hayashi K., Imai K. et al. Idiopathic myoclonic-astatic epilepsy of early childhood – nosology based on electrophysiologic and long-term follow up study of patients. Adv Neurol 2005;95:157–74.Quade A., Thiel A., Kurth I. et al. Paroxysmal tonic upgaze: A heterogeneous clinical condition responsive to carbonic anhydrase inhibition. Eur J Paediatr Neurol 2020;25:181–6. DOI: 10.1016/j.ejpn.2019.11.002Panayiotopoulos C.P. A Clinical Guide to Epileptic Syndromes and Their Treatment. 2nd edn. Springer, 2010. Pp. 45–49; 325–335.Panayiotopoulos С.P. Principles of therapy in the epilepsies. In: Clinical Guide to Epileptic Syndromes and Their Treatment. Springer, 2007. Pp. 155–184.Patsalos P.N., St Louis E.K. Sulthiame. In: The Epilepsy Prescriber’s Guide to Antiepileptic Drugs. Cambridge: Cambridge University Press, 2018. Pp. 282–291.Pereira-Nunes J., Sousa J.M., Fonseca J. et al. Successful treatment of a child with epileptic encephalopathy with spike-wave activation in sleep and GRIN2A variant using sulthiame. Cureus 2023;15(2):e34686. DOI: 10.7759/cureus.34686Rahman S., Bibi S., Javed T. et al. Review: Therapeutic potential of carbonic anhydrase inhibitors. Pak J Pharm Sci 2019;32(2):709–20.Ramantani G., Bolsterli B.K., Alber M. et al. Treatment of infantile spasm syndrome: update from the interdisciplinary guideline committee coordinated by the German-Speaking Society of Neuropediatrics. Neuropediatrics 2022;53(6):389–401. DOI: 10.1055/a-1909-2977Rating D., Wolf C., Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000;41:1284–8.Reimers A., Berg J.A., Burns M.L. et al. Reference ranges for antiepileptic drugs revisited: A practical approach to establish national guidelines. Drug Des Devel Ther 2018;12:271–80. DOI: 10.2147/DDDT.S154388Riviello J.J. The Landau–Kleffner syndrome and epilepsy with continuous spike-waves during sleep. In: Pediatric Epilepsy. 4th edn. New York: Demos, 2017. Pp. 393–406.Sivathamboo S., Myers K.A., Pattichis A. et al. Sleep and respiratory abnormalities in adults with developmental and epileptic encephalopathies using polysomnography and video-EEG monitoring. Epilepsia Open 2023;8(3):1157–68. DOI: 10.1002/epi4.12772.Specchio N., Wirrell E.C., Scheffer I.E. et al. ILAE classification and definition of epilepsy syndromes with onset in childhood: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1398–442.Steinhoff B., Bast T. Compendium Antiepileptic Drugs. Berlin: Deutsche Gesellschaft für Epileptologie, 2017–2018.Steinhoff B., Bast T. Compendium Antiepileptic Drugs. Berlin: Deutsche Gesellschaft für Epileptologie, 2019–2020.Stephani U. Typical semiology of benign childhood epilepsy with centrotemporal spikes (BCECTS). Epileptic Disord 2000;2(Suppl 1):3, 4.Stephani U., Carlsson G. The spectrum from BCECTS to LKS: The rolandic EEG trait-impact on cognition. Epilepsia 2006;47(Suppl 2):67–70. DOI: 10.1111/j.1528-1167.2006.00694.xSwiderska N., Hawcutt D., Eaton V. et al. Sulthiame in refractory paediatric epilepsies: An experience of an “old” antiepileptic drug in a tertiary paediatric neurology unit. Seizure 2011;20:805–8. DOI: 10.1016/j.seizure.2011.08.006Tacke M., Borggraefe I., Gerstl L. et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: A randomized controlled trial. Seizure 2018;56:115–20. DOI: 10.1016/j.seizure.2018.01.015Tan H.J., Singh J., Gupta R., de Goede C. Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centrotemporal spikes. Cochrane Database Syst Rev 2014;2014(9):CD006779. DOI: 10.1002/14651858.CD006779.pub2Tassinari C.A., Cantaluppo G., Dalla Bernardina B. et al. Encephalopathy related to status epilepticus during slow sleep (ESES) including Landau–Kleffner syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 5th edn. Paris: John Libbey Eurotext, 2012. Pp. 255–275.Tassinari C.A., Cantaluppo G., Dalla Bernardina B. et al. Encephalopathy related to status epilepticus during slow sleep (ESES) including Landau–Kleffner syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th edn. Paris: John Libbey Eurotext, 2019. Pp. 261–283.Topcu Y., Kılıc B., Tekin H.G. et al. Effects of sulthiame on seizure frequency and EEG in children with electrical status epilepticus during slow sleep. Epilepsy Behav 2021;116:107793. DOI: 10.1016/j.yebeh.2021.107793Uliel-Sibony S., Chernuha V., Tokatly Latzer I., Leitner Y. Epilepsy and attention-deficit/hyperactivity disorder in children and adolescents: An overview of etiology, prevalence, and treatment. Front Hum Neurosci 2023;17:1021605.Verrotti A., Moavero R., Panzarino G. et al. The challenge of pharmacotherapy in children and adolescents with epilepsy-ADHD comorbidity. Clin Drug Investig 2018;38:1–8.Wirrell E.С., Nabbout R., Scheffer I. et al. Methodology for classification and definition of epilepsy syndromes: Report of the ILAE Task Force on nosology and definitions. Epilepsia 2022;63(6):1333–48.